{"filing":{"accession_number":"0001213900-26-077296","cik":"0001514183","ticker":"SILO","company_name":"Silo Pharma, Inc.","form":"8-K","filing_date":"2026-07-10","report_date":null,"primary_document":"ea0297602-8k_silo.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026077296/ea0297602-8k_silo.htm"},"events":[{"id":17428,"run_id":15603,"accession_number":"0001213900-26-077296","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Silo Pharma entered into securities purchase agreements on July 9, 2026, for a private placement of 619,965 shares of common stock (or pre-funded warrants), Series A-3 and A-4 warrants, raising approximately $4 million upfront with potential additional proceeds of ~$7.7 million upon warrant exercise. The unregistered securities were issued under Section 4(a)(2) and Regulation D exemptions, with a registration rights agreement for resale.","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-07-10","form":"8-K","submitted_at":null,"items":[{"id":15894,"accession_number":"0001213900-26-077296","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Silo Pharma entered into securities purchase agreements on July 9, 2026, for a private placement of common stock, pre-funded warrants, and Series A-3 and A-4 warrants. The offering raised approximately $4 million upfront with potential additional proceeds of ~$7.7 million upon warrant exercise. This is a classic dilutive equity issuance under Section 4(a)(2) and Regulation D, materially diluting existing shareholders and raising capital through unregistered securities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T10:05:13.271025+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15895,"accession_number":"0001213900-26-077296","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Silo Pharma disclosed an unregistered private placement of 619,965 shares of common stock (or pre-funded warrants), Series A-3 warrants, and Series A-4 warrants, raising approximately $4 million upfront with up to $7.7 million in potential additional proceeds from warrant exercises. The securities were issued under Section 4(a)(2) and Regulation D exemptions, and the company agreed to file a resale registration statement. This is a classic dilutive equity issuance by a developmental-stage biopharmaceutical company raising capital through a PIPE-like structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T10:05:13.271025+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15896,"accession_number":"0001213900-26-077296","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Silo Pharma announced a private placement of 619,965 shares of common stock (or pre-funded warrants) at $6.452 per share, generating approximately $4 million in upfront gross proceeds, plus up to $7.7 million in potential additional proceeds from warrant exercises. The securities are unregistered and issued under Section 4(a)(2) and Regulation D, with a registration rights agreement for resale. This is a classic dilutive equity issuance by a small-cap developmental-stage biopharmaceutical company raising capital through a private placement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T10:05:13.271025+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15894,"accession_number":"0001213900-26-077296","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Silo Pharma entered into securities purchase agreements on July 9, 2026, for a private placement of common stock, pre-funded warrants, and Series A-3 and A-4 warrants. The offering raised approximately $4 million upfront with potential additional proceeds of ~$7.7 million upon warrant exercise. This is a classic dilutive equity issuance under Section 4(a)(2) and Regulation D, materially diluting existing shareholders and raising capital through unregistered securities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T10:05:13.271025+00:00","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-07-10"},{"id":15895,"accession_number":"0001213900-26-077296","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Silo Pharma disclosed an unregistered private placement of 619,965 shares of common stock (or pre-funded warrants), Series A-3 warrants, and Series A-4 warrants, raising approximately $4 million upfront with up to $7.7 million in potential additional proceeds from warrant exercises. The securities were issued under Section 4(a)(2) and Regulation D exemptions, and the company agreed to file a resale registration statement. This is a classic dilutive equity issuance by a developmental-stage biopharmaceutical company raising capital through a PIPE-like structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T10:05:13.271025+00:00","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-07-10"},{"id":15896,"accession_number":"0001213900-26-077296","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Silo Pharma announced a private placement of 619,965 shares of common stock (or pre-funded warrants) at $6.452 per share, generating approximately $4 million in upfront gross proceeds, plus up to $7.7 million in potential additional proceeds from warrant exercises. The securities are unregistered and issued under Section 4(a)(2) and Regulation D, with a registration rights agreement for resale. This is a classic dilutive equity issuance by a small-cap developmental-stage biopharmaceutical company raising capital through a private placement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T10:05:13.271025+00:00","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-07-10"}]}